title: A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis.
abstract: OBJECTIVE
  Compare two dosage strengths of levofloxacin in the treatment of acute bacterial sinusitis.
  
  
  METHODS
  Multicenter clinical trial comparing levofloxacin 750 mg for 5 days vs levofloxacin 500 mg for 10 days.
  
  
  RESULTS
  Sinus fluid samples were obtained by antral puncture (59.2%) or by sinus endoscopy (40.8%). Among microbiologically evaluable patients, 91.4% (139/152) of patients receiving levofloxacin 750 mg achieved clinical success vs 88.6% (132/149) of patients receiving levofloxacin 500 mg (95% CI -10.0, 4.2). Clinical success rates by pathogen were above 90% in both treatment groups for the 3 typical pathogens of acute sinusitis: Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The safety profile of the 2 dosage strengths was similar.
  
  
  CONCLUSIONS
  Levofloxacin 750 mg for 5 days is noninferior to levofloxacin 500 mg for 10 days.
  
  
  CONCLUSIONS
  Levofloxacin 750 mg for 5 days represents a safe and effective treatment regimen for acute bacterial sinusitis.
  
  
  METHODS
  A-1b.
authors.affiliation: Georgia Ear Institute, Savannah, Georgia, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Poole
authors.forename: Jack
authors.initials: J
authors.lastname: Anon
authors.forename: Margaret
authors.initials: M
authors.lastname: Paglia
authors.forename: Jim
authors.initials: J
authors.lastname: Xiang
authors.forename: Mohammed
authors.initials: M
authors.lastname: Khashab
authors.forename: James
authors.initials: J
authors.lastname: Kahn
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage*; D011446:Prospective Studies; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin